India has recorded 69878 cases of coronavirus in the last 24 hours, bringing its total to 2975701. With 953 deaths reported on Friday, the death toll in the country increased to 55,928. India remained the third most affected country in the world after the US and Brazil, the knowledge of the EU Ministry of Health showed Saturday.
The number of active instances 697,330 and 55,794 others died from a viral disease, according to data. The cure rate rose to 74.69%, with a record 63,631 Covid-19 patients discharged from hospitals in the last 24 hours. There are 2222577 other people who have cured of coronavirus disease to date.
No fewer than 23,120,802 other international people have been diagnosed with Covid-19. While 15,714,993 have recovered, 803,213 have died to date.
Here are all the latest updates on Covid-19 in India and developments:
India will see only about 57,000 deaths until the end of Saturday, of which some 16,000 will be recorded since the two million mark crossed. A little more than 13,000 of them were recorded between the time it passed through one million instances and affected two million.
The third million instances largely reflected the trend of the latter. Maharashtra accounted for 18.6% of the million, Andhra Pradesh 14.9%, Karnataka 11.1% and Tamil Nadu 9.3%. Uttar Pradesh and Bihar, two of India’s most populous states, accounted for 7.2% and 5.3% of one million cases. West Bengal accounted for 4.8% of cases and Assam accounted for 3.9%. Delhi accounted for only 1.8% of cases.
British pharmaceutical giant AstraZeneca has partnered with the Serum Institute of India (SII) in Pune to produce one billion doses for low-income countries, adding India. The Comptroller General of Medicines of India (DCGI) had already given the green light to conduct a Phase II/III trial of the Oxford vaccine in India. The trials are being conducted at 17 determined sites across India with 1,600 volunteers, in addition to THE KEM and Nair hospitals in Mumbai.
The Union’s Minister of Health and Family Welfare, Dr. Harsh Vardhan, in an interview with the Hindustan Times, said vaccine trials opposed to Covid-19 were accelerating around the world. “Indian-based vaccine trials are expected to be completed until the end of this year. Then we will know the effectiveness of vaccines. The Oxford vaccine produced through the Serum Institute of India is already produced in parallel, so the time required to market will be reduced to a greater extent”.
As the race for the coronavirus vaccine intensifies, the United States faces a possible crisis: the shortage of syringes. The U.S. federal government He has already spent millions of dollars in the hope of avoiding syringe shortages, as long as a Covid-19 vaccine is approved. This comes at a time when the shortage of private protective devices continues to hamper the pandemic reaction.
India does not plan to stick to a predefined benchmark for choosing a Covid-19 vaccine and will explore all the features available for mass contagion vaccination. “When we have a vaccine ready, we will examine all the parameters in a balanced way, their effectiveness, their cost, their ease of administration, as well as other factors,” Dr. V.K. said. Paul, member of NITI Aayog (health) and chair of the National Panel on Vaccine Management.
Bangladesh will be a previous recipient of the Covid-19 vaccine developed in India, according to Foreign Secretary Harsh Vardhan Shringla. “For us, Bangladesh is still a country of precedence,” said Shringla, who is here in two days here through local media, told reporters here Wednesday after being asked about vaccines.
“O item.title”